

Application No. 10/580,588  
Paper Dated: February 14, 2008  
In Reply to USPTO Correspondence of January 16, 2008  
Attorney Docket No. 3824-061668

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/580,588 Confirmation No. 5444  
Applicant : YUTAKA SASHIDA et al.  
Filed : May 25, 2006  
Title : Novel Compound and Pharmaceutical Composition  
Group Art Unit : 1625  
Examiner : Nizal S. Chandrakumar  
Customer No. : 28289

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Applicants hereby respond to the Office Action dated January 16, 2008, in connection with the above-identified application.

The Examiner has requested election and restriction between Group 1, including claims 36-38, 55 and 70, covering compounds; Group 2, including claims 39-44 and 56-59, covering pharmaceutical methods of using compounds; and Group 3, including claims 45-54 and 60-69, covering chromatographic methods of purifying compounds.. Applicants elect to prosecute the claims of Group 1 and reserve the right to file divisional applications or take such other appropriate measure as they deem necessary to protect their inventions lying within Groups 2 and 3.


I hereby certify that this correspondence is being electronically submitted to the United States Patent and Trademark Office on February 14, 2008.

02/14/2008 Linda L. Marlowe  
\_\_\_\_\_  
Date Signature  
\_\_\_\_\_  
Linda L. Marlowe  
Typed Name of Person Signing Certificate

Application No. 10/580,588  
Paper Dated: February 14, 2008  
In Reply to USPTO Correspondence of January 16, 2008  
Attorney Docket No. 3824-061668

Examination and allowance of claims 36-38, 55 and 70 are respectfully requested.

Respectfully submitted,  
THE WEBB LAW FIRM

By 

Richard L. Byrne  
Registration No. 28,498  
Attorney for Applicants  
436 Seventh Avenue  
700 Koppers Building  
Pittsburgh, PA 15219  
Telephone: (412) 471-8815  
Facsimile: (412) 471-4094  
E-mail: webblaw@webblaw.com